Henricus G Ruhé1, Jochanan Huyser, Jan A Swinkels, Aart H Schene. 1. c/o Mrs M. Haages, Out-patient Department of Psychiatry A3-255.1, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands. H.G.Ruhe@amc.uva.nl
Abstract
BACKGROUND: Although selective serotonin reuptake inhibitors (SSRIs) are frequently used for major depressive disorder, only 50-60% of patients respond to a standard dose. For non-responders, dose escalation is often applied. AIM: To systematically review the evidence for dose escalation of SSRIs. METHOD: A systematic literature search in MEDLINE, EMBASE, CINAHL and PsycInfo was performed. Randomised controlled trials and meta-analyses investigating dose escalation of SSRIs were identified. Relevant articles were retrieved and critically appraised. Results were summarised in an evidence table. Pooling was not justified because of heterogeneity of the identified studies. RESULTS: Eight true dose-escalation studies and three meta-analyses were identified. The available data provided no unequivocal base for dose escalation. Dose escalation before 4 weeks of treatment at a standard dose appeared to be ineffective. CONCLUSIONS: Dose escalation of SSRIs is equivocally supported by evidence of randomised controlled trials; methodological difficulties in the studies may account for this lack of evidence.
BACKGROUND: Although selective serotonin reuptake inhibitors (SSRIs) are frequently used for major depressive disorder, only 50-60% of patients respond to a standard dose. For non-responders, dose escalation is often applied. AIM: To systematically review the evidence for dose escalation of SSRIs. METHOD: A systematic literature search in MEDLINE, EMBASE, CINAHL and PsycInfo was performed. Randomised controlled trials and meta-analyses investigating dose escalation of SSRIs were identified. Relevant articles were retrieved and critically appraised. Results were summarised in an evidence table. Pooling was not justified because of heterogeneity of the identified studies. RESULTS: Eight true dose-escalation studies and three meta-analyses were identified. The available data provided no unequivocal base for dose escalation. Dose escalation before 4 weeks of treatment at a standard dose appeared to be ineffective. CONCLUSIONS: Dose escalation of SSRIs is equivocally supported by evidence of randomised controlled trials; methodological difficulties in the studies may account for this lack of evidence.
Authors: Ewgeni Jakubovski; Anjali L Varigonda; Nicholas Freemantle; Matthew J Taylor; Michael H Bloch Journal: Am J Psychiatry Date: 2015-11-10 Impact factor: 18.112
Authors: Yuen-Siang Ang; Roselinde Kaiser; Thilo Deckersbach; Jorge Almeida; Mary L Phillips; Henry W Chase; Christian A Webb; Ramin Parsey; Maurizio Fava; Patrick McGrath; Myrna Weissman; Phil Adams; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Thomas Carmody; Gerard Bruder; Crystal M Cooper; Cherise R Chin Fatt; Madhukar H Trivedi; Diego A Pizzagalli Journal: Biol Psychiatry Date: 2020-04-23 Impact factor: 13.382
Authors: Richard A Hansen; Charity G Moore; Stacie B Dusetzina; Brian I Leinwand; Gerald Gartlehner; Bradley N Gaynes Journal: Med Decis Making Date: 2009-01-13 Impact factor: 2.583
Authors: Bruce L Rollman; Bea Herbeck Belnap; Michelle S LeMenager; Sati Mazumdar; Herbert C Schulberg; Charles F Reynolds Journal: Psychosom Med Date: 2009-02-02 Impact factor: 4.312
Authors: James H Kocsis; Alan J Gelenberg; Barbara Rothbaum; Daniel N Klein; Madhukar H Trivedi; Rachel Manber; Martin B Keller; Robert Howland; Michael E Thase Journal: J Affect Disord Date: 2008-02-12 Impact factor: 4.839
Authors: M E Haahr; P M Fisher; C G Jensen; V G Frokjaer; B Mc Mahon; K Madsen; W F C Baaré; S Lehel; A Norremolle; E A Rabiner; G M Knudsen Journal: Mol Psychiatry Date: 2013-11-05 Impact factor: 15.992